

Abstract

Rosiglitazone Maleate is used for management of type-2 diabetes. It is an absorption window limited drug, whose solubility decreases with increase in the pH and has a short half life of 3-4 h. Therefore the present investigation is concerned with the development of the floating matrix tablets, which after oral administration were designed to prolong the gastric residence time and thus to increase the bioavailability of the drug and its half life